Arbutus Biopharma
Publicly-traded biopharmaceutical company.
Launch date
Employees
Market cap
€741m
Enterprise valuation
€614m (Public information from Sep 2024)
Share price
$4.13 ABUS
Warminster Township Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.9m | 11.0m | 39.0m | 18.1m | 7.2m | 6.3m | 8.7m |
| % growth | 15 % | 59 % | 255 % | (54 %) | (60 %) | (12 %) | 37 % |
| EBITDA | (57.1m) | (71.5m) | (61.0m) | (70.9m) | - | - | - |
| % EBITDA margin | (826 %) | (651 %) | (156 %) | (391 %) | - | - | - |
| Profit | (63.7m) | (76.2m) | (69.5m) | (72.8m) | (74.3m) | (73.0m) | (85.4m) |
| % profit margin | (922 %) | (694 %) | (178 %) | (402 %) | (1031 %) | (1153 %) | (986 %) |
| EV / revenue | 40.7x | 44.4x | 9.3x | 22.4x | 100.4x | 114.1x | 83.5x |
| EV / EBITDA | -4.9x | -6.8x | -5.9x | -5.7x | - | - | - |
| R&D budget | 47.5m | 65.5m | 84.4m | 73.7m | - | - | - |
| R&D % of revenue | 687 % | 596 % | 216 % | 406 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | N/A | - |
| N/A | N/A | IPO | |
| N/A | CAD5.1m | Post IPO Equity | |
$3.0m | Post IPO Debt | ||
* | N/A | $60.6m | Post IPO Equity |
* | N/A | $152m | Post IPO Equity |
$116m | Post IPO Equity | ||
| Total Funding | - | ||
Recent News about Arbutus Biopharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.